ArticleEpidemics2016
Dengue serotype immune-interactions and their consequences for vaccine impact predictions.
Article in Epidemics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The biting rate of Aedes aegypti and its variability: A systematic review (1970-2022).PLoS neglected tropical diseases · 2023Pooled it
- Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines.Drug safety · 2020Pooled it
- Shifting patterns of dengue three years after Zika virus emergence in Brazil.Nature communications · 2024Article
- Short-term and long-term epidemiological impacts of sustained vector control in various dengue endemic settings: A modelling study.PLoS computational biology · 2022Article
- The Global Trends and Regional Differences in Incidence of Dengue Infection from 1990 to 2019: An Analysis from the Global Burden of Disease Study 2019.Infectious diseases and therapy · 2021Article
- Pneumococcal Competition Modulates Antibiotic Resistance in the Pre-Vaccination Era: A Modelling Study.Vaccines · 2021Article
- Migration rate estimation in an epidemic network.Applied mathematical modelling · 2021Article
- Simulation models of dengue transmission in Funchal, Madeira Island: Influence of seasonality.PLoS neglected tropical diseases · 2020Article
- Modelling the Use of Vaccine andTropical medicine and infectious disease · 2020Article
- Article
- Alanine Substitution Inactivates Cross-Reacting Epitopes in Dengue Virus Recombinant Envelope Proteins.Viruses · 2020Article
- MVSE: An R-package that estimates a climate-driven mosquito-borne viral suitability index.Methods in ecology and evolution · 2019Article
- Reverse immunodynamics: a new method for identifying targets of protective immunity.Scientific reports · 2019Article
- A multi-country study of the economic burden of dengue fever based on patient-specific field surveys in Burkina Faso, Kenya, and Cambodia.PLoS neglected tropical diseases · 2019Article
- Challenges in dengue research: A computational perspective.Evolutionary applications · 2018Review
- Early warning signal for dengue outbreaks and identification of high risk areas for dengue fever in Colombia using climate and non-climate datasets.BMC infectious diseases · 2017Article
- HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus.Frontiers in microbiology · 2017Article
- The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.PLoS medicine · 2016Article
- DengueME: A Tool for the Modeling and Simulation of Dengue Spatiotemporal Dynamics.International journal of environmental research and public health · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Dengue is one of the most important and wide-spread viral infections affecting human populations. The last few decades have seen a dramatic increase in the global burden of dengue, with the virus now being endemic or near-endemic in over 100 countries world-wide. A recombinant tetravalent vaccine candidate (CYD-TDV) has recently completed Phase III clinical efficacy trials in South East Asia and Latin America and has been licensed for use in several countries. The trial results showed moderate-to-high efficacies in protection against clinical symptoms and hospitalisation but with so far unknown effects on transmission and infections per se. Model-based predictions about the vaccine's short- or long-term impact on the burden of dengue are therefore subject to a considerable degree of uncertainty. Furthermore, different immune interactions between dengue's serotypes have frequently been evoked by modelling studies to underlie dengue's oscillatory dynamics in disease incidence and serotype prevalence. Here we show how model assumptions regarding immune interactions in the form of antibody-dependent enhancement, temporary cross-immunity and the number of infections required to develop full immunity can significantly affect the predicted outcome of a dengue vaccination campaign. Our results thus re-emphasise the important gap in our current knowledge concerning the effects of previous exposure on subsequent dengue infections and further suggest that intervention impact studies should be critically evaluated by their underlying assumptions about serotype immune-interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.